FDA/PhRMA Task Force To Assess QT Risk By Preclinical Markers

FDA and the Pharmaceutical Research & Manufacturers of America are forming a joint task force to define a preclinical threshold to serve as a predictor for the risk of drug-associated QT prolongation.